Przemek Obloj
CFO at bit.bio
United Kingdom
Overview
Work Experience
Chief Executive Officer
2025 - Current
bit.bio is a synthetic biology company creating and manufacturing human cells to enable biomedical research and cell therapy. It was spun out of the University of Cambridge in 2016 and has since raised over $200m from investors such as Arch Venture, Foresite Capital, Milky Way, Charles River Laboratories, National Resilience, Tencent, Verition Fund and Puhua Capital. bit.bio’s opti-ox™ precision cell programming and manufacturing technology enables conversion of induced pluripotent stem cells (iPSCs) into any desired human cell type. This can be achieved within days and at industrial scale, while maintaining exceptional purity and unparalleled consistency.
Investor
2021
Chief Financial Officer
2024 - 2025
Investment Advisory Board Member
2020
Managing Partner & CIO
2020 - 2023
Managing Director, Head of European Private Equity
2016 - 2020
Private Equity and Growth investing across Europe and the U.S.
Director
2009 - 2016
Investor
2007 - 2009
Analyst / Associate / Manager, Private Equity & Corporate Finance Practice
2000 - 2007
McKinsey Growth Tech serves leading growth stage tech players, venture capital, and growth private equity
Analyst / Data Scientist
1998 - 2000
Provided data and analytical support to the Minister of Labour implementing a comprehensive pension reform in Poland, including a switch to a defined contribution scheme and introduction of pension funds